GEN Exclusives

More »

GEN News Highlights

Back to Item »

Celgene Pays Epizyme $90M for Ex-U.S. Rights to Histone Methyltransferase Inhibitor

Deal gives Celgene license to lead DOT1L candidate and option to other HTM inhibitors.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »